Etodolac
- Atc Codes:M01AB08
- CAS Codes:41340-25-4
- PHARMGKB ID:41340-25-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Denmark: Todolac; Finland: Lodine; Portugal: Dualgan, Exodolan, Sodolac; Romania: Etol; Slovenia: Elderin; UK: Eccoxolac, Lodine.
North America
Canada: Etodolac; USA: Etodolac.
Latin America
Brazil: Flancox.
Asia
Japan: Etopen, Hisrack, Hypen, Niconas, Ospain, Osteluc, Paipelac, Raipeck.
Drug combinations
Chemistry
Etodolac: C~17~H~21~NO~3~. Mw: 287.35. (1) Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(±)-; (2)(±)-1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid. CAS-41340-25-4 (1975).
Pharmacologic Category
Other Nonsteroidal Anti-inflammatory Agents. (ATC-Code: M01AB08).
Mechanism of action
Prototypical NSAID. Inhibits prostaglandin synthesis by decreasing activity of the enzyme cyclooxygenase, resulting in decreased formation of prostaglandin precursors.
Therapeutic use
Used for anti-inflammatory and analgesic effects in acute and chronic symptomatic treatment of osteoarthritis and rheumatoid arthritis. Also used for symptomatic treatment of juvenile rheumatoid arthritis in pediatric patients 6-16 years of age and for the relief of pain.
Pregnancy and lactiation implications
This drug should not be used in the 3^rd^ trimester of pregnancy.
Unlabeled use
Contraindications
Hypersensitivity to etodolac, aspirin, other NSAIDs, or any component of the formulation. Perioperative pain in the setting of coronary artery bypass graft surgery.
Warnings and precautions
Anaphylactoid reactions might occur (even without prior exposure). Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy. Platelet adhesion and aggregation may be decreased; may prolong bleeding time (use caution in coagulation disorders or patients receiving anticoagulants). Anemia might occur. NSAIDs are associated with increased risk of adverse cardiovascular thrombotic events, including MI, stroke, and new onset or worsening of pre-existing hypertension (use caution with fluid retention, heart failure, or hypertension). NSAIDs may increase risk of GI irritation, inflammation, ulceration, bleeding, and perforation (use caution in history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, elderly or debilitated patients). NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur (use caution in other forms of asthma). Use contraindicated for treatment of perioperative pain in setting of CABG surgery. Risk of MI and stroke may be increased with use following CABG surgery. Use with caution in decreased hepatic function. Severe hepatic reactions (e.g. fulminant hepatitis, liver failure) have occurred with NSAID use (rarely). NSAID use may compromise existing renal function (patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACEIs, and the elderly are at greater risk for renal toxicity). Not recommended for use in advanced renal disease. Long-term NSAID use may result in renal papillary necrosis. The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs, even at low doses. Use of extended release product consisting of a nondeformable matrix should be avoided in stricture/narrowing of the GI tract. Withhold for at least 4-6 half-lives prior to surgical or dental procedures.